ARTICLE
23 January 2017

Construction Of A Claim Term By The PTAB Does Not Negate Indefiniteness

SS
Seyfarth Shaw LLP

Contributor

With more than 900 lawyers across 18 offices, Seyfarth Shaw LLP provides advisory, litigation, and transactional legal services to clients worldwide. Our high-caliber legal representation and advanced delivery capabilities allow us to take on our clients’ unique challenges and opportunities-no matter the scale or complexity. Whether navigating complex litigation, negotiating transformational deals, or advising on cross-border projects, our attorneys achieve exceptional legal outcomes. Our drive for excellence leads us to seek out better ways to work with our clients and each other. We have been first-to-market on many legal service delivery innovations-and we continue to break new ground with our clients every day. This long history of excellence and innovation has created a culture with a sense of purpose and belonging for all. In turn, our culture drives our commitment to the growth of our clients, the diversity of our people, and the resilience of our workforce.
The doctrine of definiteness requires a patent to clearly state what the inventor considers to be their invention.
United States Intellectual Property

The doctrine of definiteness requires a patent to clearly state what the inventor considers to be their invention. Of course, the PTAB interprets various claim terms when determining whether a prior art reference anticipates or renders obvious a particular claim. So what happens when an accused infringer challenges a claim before the PTAB, and after a PTAB claim interpretation, then challenges the definiteness of that same claim term in district court?

The case of Depomed, Inc. v. Purdue Pharma, L.P., Civil Action No. 13-571 (MLC) (D. NJ) considered this very issue. Depomed sought to preclude Purdue Pharma from amending their invalidity contentions to assert indefiniteness after the 2014 Supreme Court Nautilus decision changed the standard for definiteness. Among other things, Depomed argued the PTAB had already construed the term "substantially all of said drug" so any such assertion of indefiniteness would have been futile.

The court disagreed, first noting that indefiniteness is not a basis for arguing invalidity before the PTAB. Indefiniteness is often challenged during claim construction in district courts, but Purdue Pharma could not have raised this issue before the PTAB when construing the terms of the relevant claims because indefiniteness is not an available argument before the PTAB. Depomed also argued the challenge was futile because courts in the same district had construed the term at issue. The court also rejected this argument because those constructions were pre-Nautilus and therefore under a different standard for indefiniteness.

Takeaway:

Indefiniteness is a popular invalidity argument post-Nautilus with what many believe to be a lower standard for invalidating a confusing or otherwise indefinite claim. Defendants often litigate and file PTAB proceedings in parallel, and this decision suggests defendants can seek construction of confusing terms before the PTAB without fearing the preclusion of a district court indefiniteness argument.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More